Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to $300000.0.

  • Fulcrum Therapeutics' Depreciation and Depletion fell 2500.0% to $300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 2355.56%. This contributed to the annual value of $1.6 million for FY2024, which is 2727.27% down from last year.
  • As of Q3 2025, Fulcrum Therapeutics' Depreciation and Depletion stood at $300000.0, which was down 2500.0% from $300000.0 recorded in Q2 2025.
  • Over the past 5 years, Fulcrum Therapeutics' Depreciation and Depletion peaked at $700000.0 during Q2 2021, and registered a low of $300000.0 during Q2 2025.
  • For the 5-year period, Fulcrum Therapeutics' Depreciation and Depletion averaged around $516894.7, with its median value being $536000.0 (2022).
  • In the last 5 years, Fulcrum Therapeutics' Depreciation and Depletion surged by 2000.0% in 2021 and then tumbled by 3333.33% in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Depreciation and Depletion stood at $615000.0 in 2021, then decreased by 3.9% to $591000.0 in 2022, then dropped by 15.4% to $500000.0 in 2023, then fell by 24.8% to $376000.0 in 2024, then fell by 20.21% to $300000.0 in 2025.
  • Its last three reported values are $300000.0 in Q3 2025, $300000.0 for Q2 2025, and $400000.0 during Q1 2025.